Roche Immunotherapy Combination Increases Lung Cancer Survival - Study | Latest News RSS feed WooCommerce

Roche Immunotherapy Combination Increases Lung Cancer Survival - Study - Latest News


Roche immunotherapy combination increases lung cancer survival-study

May 16 (Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination with... read more

Study preserves hopes for Roche's Tecentriq in lung cancer

“These are the first positive Phase III survival results for any immunotherapy-based combination ... lung cancer,” Horning said. Roche shares were seen rising 1.1 percent, according to pre-market indi... read more

Combination therapy doubles survival in metastatic lung cancer

The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer ... % in the combination group and 65.8% in the standar... read more

Looking for another news?


J&J puts the brakes on immunotherapy combination studies

The maker of a drug approved to treat the blood cancer ... of deaths among lung cancer patients receiving the combination. Janssen – a division of Johnson & Johnson – terminated a Phase I/IIb study of ... read more

Jetpack

Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Roche’s RHHBY member ... The Tecentriq study is the first phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival for the first-line treatment of advance... read more

Study preserves hopes for Roche’s Tecentriq in lung cancer

Small cell lung ... immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer,” Horning said. Roche shares were seen rising by 1.1%, according to pre-market in... read more

Roche immunotherapy combination increases lung cancer survival-study

(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tec... read more

Roche immunotherapy combination increases lung cancer survival - study

(Reuters) - Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tec... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us